Anti-CXCL13 antibodies
AssigneeI-Mab Biopharma US Limited
InventorsHaijuan Gu, Qiumei Yang
Life of this patent
Estimating the term…
Abstract
Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL 13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
Claims14
An antibody or fragment thereof having specificity to a human chemokine (C-X-C motif) ligand 13 (CXCL13) protein, wherein the antibody or fragment thereof comprises a heavy chain variable region comprising heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein:
- the HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 127 (RYWMS);
- the HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 128 (EINPDSSTINY APSLKD);
- the HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 130 (QDDYEYYAMDY);
- the LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 131 (KASQDVNTGVA);
- the LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 132 (SASYRYT);
- and the LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 133 (QQYYSTPLT), or
- the HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 127 (RYWMS);
- the HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 129 (EINPESSTINYAPSLKD);
- the HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 130 (QDDYEYYAMDY);
- the LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 131 (KASQDVNTGVA);
- the LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 132 (SASYRYT);
- and the LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 133 (QQYYSTPLT), or
- the HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 127 (RYWMS);
- the HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 129 (EINPESSTINYAPSLKD);
- the HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 359 (QDDYEYYTMDY);
- the LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 360 (KVSQDVNTGVA),
- The LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 132 (SASYRYT);
- the LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 361 (QQYWSTPLT), or
- the HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 127 (RYWMS);
- the HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 129 (EINPESSTINYAPSLKD);
- the HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 359 (QDDYEYYTMDY);
- the LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 360 (KVSQDVNTGVA),
- the LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 132 (SASYRYT);
- and the LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 133 (QQYYSTPLT), or
- the HCDR1 comprises the amino acid sequence of SEQ ID NO:
- 127 (RYWMS);
- the HCDR2 comprises the amino acid sequence of SEQ ID NO:
- 129 (EINPESSTINYAPSLKD);
- the HCDR3 comprises the amino acid sequence of SEQ ID NO:
- 367 (QDDYETYTMDY),
- the LCDR1 comprises the amino acid sequence of SEQ ID NO:
- 360 (KVSQDVNTGVA),
- the LCDR2 comprises the amino acid sequence of SEQ ID NO:
- 132 (SASYRYT);
- and the LCDR3 comprises the amino acid sequence of SEQ ID NO:
- 133 (QQYYSTPLT).
Dependencies are inferred from the claim text.